AEGEAN Early stage (operable) NSCLC - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn if the study drug will work (delay the cancer coming back) and to find out if it is safe when combined with chemotherapy for operable lung cancer.
Early Stage (stages 2 or 3, operable) Non-Small Cell Lung Cancer
Who Can Participate in the Study?
-Have a diagnosis of operable stage 2 or 3 non-small cell lung cancer
For more information on who can participate in this study please contact the study team.
What is Involved?
If you choose to join this study, you will:
-Have a physical exam
-Have blood samples taken
-Have scans to measure your tumor
-Be assigned by chance (a fair 50/50 chance) to group1 or Group 2
---Group 1 will get the study drug (durvalumab) plus chemotherapy over 12 weeks before surgery
---Group 2 will get a placebo (harmless, inactive substance) over 12 weeks plus chemotherapy before surgery
After surgery, you will receive just study drug or the placebo for up to one year.